| セッション情報 |
ポスターセッション(消化器内視鏡学会)
胃-ESD3
|
| タイトル |
内P-15：Effect of Surgicel® (Fibrillar) on prevention for ulcer bleeding after ESD of gastric epithelial tumors
|
| 演者 |
J. H. Choi（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine） |
| 共同演者 |
S. J. Hong（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine）, J. P. Han（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine）, Y. H. Cho（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine）, M. J. Kim（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine）, B. M. Ko（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine）, M. S. Lee（Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine） |
| 抄録 |
Aims: Surgicel® (Fibrillar) is oxidized regenerated cellulose and absorbable hemostats, and has used to control of oozing bleeding. We assessed the effect of Surgicel® on preventing bleeding after endoscopic submucosal dissection (ESD).Methods: Patients scheduled for ESD to treat the gastric epithelial tumors were enrolled in this study. Patients were assigned to combination therapy with Surgicel® and H2 receptor antagonist (H2RA) or monotherapy with proton pump inhibitor (PPI) after ESD. Bleeding rate and change of hemoglobin (Hb) were assessed to evaluate the effect on preventing ulcer bleeding after ESD.Results: Among 116 patients (87 male, 29 female), 59 patients were assigned to combination therapy with Surgicel® and H2RA and 57 patients to monotherapy with PPI. There was no significant difference in major bleeding (combination therapy 5.1%, monotherapy 3.6%, P=1.000). However, the laboratory result showed there was significant change of Hb (7 days after ESD) between two groups (-0.6±1.3 in combination therapy, -1.2±1.3 in monotherapy, P=0.013). Conclusions: Combination therapy with Surgicel® and H2RA had similar effect on preventing major ulcer bleeding after ESD for gastric epithelial tumors, compared to monotherapy with PPI. Moreover, Surgicel® enables oozing bleeding to be discontinued, resulting in preventing reduction of Hb. |
| 索引用語 |
Surgicel, Endoscopic submucosal dissection |
